| Literature DB >> 23983804 |
Wolfgang Kemmler1, Simon von Stengel, Michael Bebenek, Willi A Kalender.
Abstract
In female subjects, ageing and the menopausal transition contribute to a rapid increase of metabolic and cardiac risk factors. Exercise may be an option to positively impact various risk factors prone to severe metabolic and cardiac diseases and events. This study was conducted to determine the long-term effect of a multipurpose exercise program on metabolic and cardiac risk scores in postmenopausal women. 137 osteopenic Caucasian females (55.4 ± 3.2 yrs), 1-8 years postmenopausal, were included in the study. Eighty-six subjects joined the exercise group (EG) and performed an intense multipurpose exercise program which was carefully supervised during the 12-year period, while 51 females maintained their habitual physical activity (CG). Main outcome measures were 10-year coronary heart disease risk (10 y CHD risk), metabolic syndrome Z-score (MetS Index), and 10-year myocardial infarction risk (10 y hard CHD risk). Significant between-group differences all in favor of the EG were determined for 10 y-CHD risk (EG: 2.65 ± 2.09% versus CG: 5.40 ± 3.30%; P = 0.001), MetS-Index (EG: -0.42 ± 1.03% versus CG: 1.61 ± 1.88; P = 0.001), and 10 y-hard-CHD risk (EG: 2.06 ± 1.17% versus CG: 3.26 ± 1.31%; P = 0.001). Although the nonrandomized design may prevent definite evidence, the intense multi-purpose exercise program determined the long-term efficacy and feasibility of an exercise program to significantly impact metabolic and cardiac risk scores in postmenopausal women. This trial is registered with ClinicalTrials.gov NCT01177761.Entities:
Year: 2013 PMID: 23983804 PMCID: PMC3745878 DOI: 10.1155/2013/768431
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Extended flow chart of the EFOPS study.
Baseline characteristics of the exercise and the control groups.
| Variable | Exercise | Control |
|---|---|---|
| Age (years) | 54.8 ± 3.6 | 55.8 ± 3.2 |
| Body mass index (kg/m2) | 24.8 ± 3.0 | 25.6 ± 3.6 |
| Body fat (%)b | 35.8 ± 4.6 | 35.2 ± 5.8 |
| Age at menarche (years)a | 13.1 ± 1.4 | 13.3 ± 1.6 |
| Age at menopause (years)a | 50.6 ± 3.1 | 50.6 ± 3.3 |
| Volume of exercise (min/week)a | 89 ± 84 | 75 ± 66 |
| Physical activity (Index)a,c | 4.1 ± 1.2 | 4.0 ± 1.3 |
| VO2 peak (mL/min/kg)d | 25.3 ± 6.3 | 25.3 ± 5.9 |
| Energy intake (MJ/d)e | 7.75 ± 1.39 | 7.69 ± 1.85 |
| Fat intake (% of energy intake)e | 35 ± 8 | 36 ± 7 |
| Smokers (%)a | 14 | 12 |
| Diabetes (%)a | 4 | 5 |
| Prevalence metabolic syndrome (%)f | 12 | 12 |
No significant between-group differences were determined. aAs determined by questionnaire; bas determined by bioimpedance analysis (Tanita BF 305, Tokyo, Japan); cas determined by physical activity questionnaire (1: very low to 7: very high) [15], dstepwise treadmill test to voluntary maximum; e5-day dietary analysis (Prodi-4.5/03, Wissenschaftlicher Verlag, Freiburg, Germany); faccording to NCEP-ATP III.
Intention to treat analysis: changes in the exercise and control groups for primary and secondary study endpoints.
| Exercise | Control | Absolute difference |
| Effect size ( | |
|---|---|---|---|---|---|
| 10-year CHD risk | |||||
| Baseline (%) | 8.42 ± 3.14 | 7.49 ± 2.72 | — | — | — |
| 12 y follow-up (%) | 10.24 ± 3.22 | 11.69 ± 2.80 | 3.89 | — | — |
| Risk changes (%) | 1.80 ± 2.16*** | 4.23 ± 3.10*** | 2.44 (1.55 to 3.33) | 0.001 | 0.91 |
|
| |||||
| Metabolic syndrome | |||||
| Baseline (%) | −2.47 ± 2.39 | −3.54 ± 2.60 | — | — | — |
| 12 y follow-up (%) | −2.72 ± 3.09 | −2.07 ± 3.44 | — | — | — |
| Changes (%) | −0.25 ± 1.44n.s. | 1.47 ± 1.76*** | 1.72 (1.17 to 2.27) | 0.001 | 1.07 |
|
| |||||
| 10-year myocardial infarction/cardiac death risk (hard 10-year CHD risk) | |||||
| Baseline (%) | 1.71 ± 1.11 | 1.62 ± 1.20 | — | — | — |
| 12 y follow-up (%) | 3.02 ± 1.56 | 4.18 ± 1.61 | — | — | — |
| Risk changes (%) | 1.31 ± 1.35*** | 2.55 ± 1.40*** | 1.23 (0.76 to 1.72) | 0.001 | 0.90 |
Significance (P) for within-group effects: ***P < 0.001; n.s.: nonsignificant.
Per protocol analysis: changes in the exercise and control groups for primary and secondary study endpoints.
| Exercise | Control | Absolute difference |
| Effect size ( | |
|---|---|---|---|---|---|
| 10-year CHD risk | |||||
| Baseline (%) | 8.39 ± 3.27 | 7.42 ± 2.58 | — | — | — |
| 12 y follow-up (%) | 11.04 ± 3.16 | 12.81 ± 3.08 | 3.89 | — | — |
| Risk changes (%) | 2.65 ± 2.09*** | 5.40 ± 3.30*** | 2.75 (1.61 to 3.89) | 0.001 | 0.90 |
|
| |||||
| Metabolic syndrome | |||||
| Baseline (%) | −2.44 ± 2.39 | −3.65 ± 2.84 | — | — | — |
| 12 y follow-up (%) | −2.88 ± 3.01 | −2.04 ± 3.77 | — | — | — |
| Changes (%) | −0.42 ± 1.03** | 1.61 ± 1.88*** | 2.03 (1.42 to 2.64) | 0.001 | 1.36 |
|
| |||||
| 10-year myocardial infarction/cardiac death risk (hard 10-year CHD risk) | |||||
| Baseline (%) | 1.78 ± 1.44 | 1.60 ± 1.26 | — | — | — |
| 12 y follow-up (%) | 3.84 ± 1.41 | 4.86 ± 2.01 | — | — | — |
| Risk changes (%) | 2.06 ± 1.17*** | 3.26 ± 1.31*** | 1.20 (0.68 to 1.71) | 0.001 | 0.97 |
Significance (P) for within-group effects: **P < 0.01, ***P < 0.001. Exact significance values are listed in the Result Section.
Changes of modifiable CHD risk factors constituting the metabolic and cardiac risk scores.
| Parameter | Exercise | Control | Absolute difference |
| Effect size ( |
|---|---|---|---|---|---|
| Waist circumference (cm) | 7.43 ± 5.42 | 11.33 ± 5.26 | 3.90 (1.70 to 6.09) | 0.001 | 0.73 |
| RR-MAP (mmHg) | −3.22 ± 5.11 | 4.65 ± 6.31 | 7.87 (5.53 to 10.21) | 0.001 | 1.37 |
| Glucose (mg/dL) | −2.80 ± 6.40 | 0.09 ± 7.89 | 2.90 (−0.03 to 5.82) | 0.052 | 0.40 |
| Triglycerides (mg/dL) | −0.1 ± 22.7 | 10.9 ± 24.9 | 11.1 (1.34 to 20.85) | 0.026 | 0.46 |
| Total cholesterol (mg/dL) | 11.9 ± 22.1 | 18.5 ± 22.2 | 6.6 (3.9 to 27.5) | 0.157 | 0.30 |
| HDL-cholesterol (mg/dL) | 7.37 ± 6.96 | 1.07 ± 8.22 | 6.30 (2.3 to 10.30) | 0.001 | 0.83 |